Evidence map›Paper›PMID 42003701›Full record

ArticleJournal of comparative effectiveness research2026

Health care resource use in the management of patients with relapsed/refractory diffuse large B-cell lymphoma - Canadian perspective.

Kimberly Guinan, Mathieu Pelletier, Monika Ham, Dipti Tankala, Nancy Paul Roc, Adi Klil-Drori, Anthony W Wang, Isabelle Fleury, David MacDonald, Jean Lachaine and 1 more

Abstract read
In one paragraph

Article in Journal of comparative effectiveness research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kimberly GuinanPeriPharm Inc., Montreal, Quebec, H2Y 1V3, Canada.ORCID 0000-0001-5245-1178
Mathieu PelletierPeriPharm Inc., Montreal, Quebec, H2Y 1V3, Canada.
Monika HamPeriPharm Inc., Montreal, Quebec, H2Y 1V3, Canada.
Dipti TankalaAbbVie Corporation, Saint-Laurent, Quebec, H4S 1Z1, Canada.ORCID 0009-0008-4849-2442
Nancy Paul RocAbbVie Corporation, Saint-Laurent, Quebec, H4S 1Z1, Canada.
Adi Klil-DroriAbbVie Corporation, Saint-Laurent, Quebec, H4S 1Z1, Canada.ORCID 0000-0001-9368-7953
Anthony W WangAbbVie Inc., North Chicago, IL 60064, USA.
Isabelle FleuryHematologist & Medical Oncologist CHU de Québec & Associate clinical professor, Laval University, Québec, QC, G1V 4W6, Canada.
David MacDonaldDivision of Hematology, Dalhousie University & QEII Health Sciences Centre, Halifax, NS, B3H 3A7, Canada.ORCID 0000-0002-7750-2733
Jean LachainePeriPharm Inc., Montreal, Quebec, H2Y 1V3, Canada.ORCID 0000-0002-0791-2518
Stephane BarakatAbbVie Corporation, Saint-Laurent, Quebec, H4S 1Z1, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsHealth ResourcesLymphoma, Large B-Cell, DiffuseCanadaCost-Benefit AnalysisHealth Care CostsHumansQuebecAntineoplastic AgentsCanadaepcoritamabHCRUhealthcare costsQuebecrelapsed-refractory DLBCL

Identifiers

PMID42003701
PMCPMC13248986

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.